PRLD

Prelude Therapeutics Inc

PRLD, USA

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

https://preludetx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRLD
stock
PRLD

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens Investing.com South Africa

Read more →
PRLD
stock
PRLD

Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$4

Analyst Picks

Strong Buy

1

Buy

2

Hold

0

Sell

1

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.22

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-33.70 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-20.82 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-294.08 %

Low 5%

High 15%

Debt to Equity

-

Medium

0.62

Low 1

High 0.3

Investors

* Institutions hold a combined 4.40% of the total shares of Prelude Therapeutics Inc

1.

Vanguard Total Stock Mkt Idx Inv

(1.2456%)

since

2025/07/31

2.

T. Rowe Price Health Sciences

(1.1554%)

since

2025/07/31

3.

Biotech Growth Ord

(0.6122%)

since

2025/05/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2519%)

since

2025/07/31

5.

Fidelity Extended Market Index

(0.1837%)

since

2025/07/31

6.

Bridgeway Ultra-Small Company Market

(0.1502%)

since

2025/06/30

7.

Schwab US Small-Cap ETF™

(0.1428%)

since

2025/08/30

8.

TD Health Sciences - I

(0.1419%)

since

2024/12/31

9.

T. Rowe Price Health Sciences Port

(0.0755%)

since

2025/07/31

10.

Fidelity Total Market Index

(0.0623%)

since

2025/07/31

11.

T. Rowe Price Health Sciences Equity Q

(0.0583%)

since

2025/07/31

12.

Fidelity Series Total Market Index

(0.0456%)

since

2025/07/31

13.

Extended Equity Market Fund K

(0.0405%)

since

2025/06/30

14.

Fidelity Nasdaq Composite Index

(0.0364%)

since

2025/07/31

15.

Spartan Extended Market Index Pool F

(0.0361%)

since

2025/07/31

16.

Northern Trust Extended Eq Market Idx

(0.0335%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - L

(0.0335%)

since

2025/06/30

18.

JHVIT Health Sciences I

(0.0308%)

since

2025/07/31

19.

JHFunds2 Health Sciences NAV

(0.0304%)

since

2025/01/31

20.

NT Ext Equity Mkt Idx Fd - NL

(0.0291%)

since

2025/06/30

21.

Royal Bank of Canada

(0.005%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.255

Latest Release

Date

2025-09-30

EPS Actual

-0.26

EPS Estimate

-0.3697

EPS Difference

0.1097

Surprise Percent

29.6727%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.